CD19 and neoplasm: For results to be comparable, we calculated the percentage of tumor cells out of the total mononuclear cells (in patients MW2, MW5, MW6 and MW7), and out of the total CD19+ cells in samples with CD19− cell depletion (i.e. MW1, MW3, MW4 and MW8).